Emerging treatments
Ceftolozane/tazobactam
Ceftolozane/tazobactam, a fifth-generation cephalosporin in combination with a beta-lactamase inhibitor, is approved in the US and Europe for the treatment of complicated UTIs (including pyelonephritis) in children. Clinical trial results published in the prescribing information for ceftolozane/tazobactam indicate that the safety profile of the antibiotic in children is similar to that observed in adults, with thrombocytosis and diarrhoea representing the most common adverse effects. Further data are needed to determine the role of ceftolozane/tazobactam in the treatment algorithm for UTI in children.
MV140
Recent studies have shown that MV140, a preparation of whole-cell inactivated bacteria, can decrease UTI incidence and prevent recurrence for up to 1 year in women, when compared with placebo.[85][86] The preparation consists of equal percentages of selected strains of four bacterial species (V121 Escherichia coli, V113 Klebsiella pneumoniae, V125 Enterococcus faecalis, and V127 Proteus vulgaris), and is administered sublingually. Further studies are required and ongoing; however, results have been promising in global literature.[87]
Use of this content is subject to our disclaimer